Reported by Guardian — US •
4 Wire-neutral provisional

✓ No loaded language, vague sourcing, or framing detected.

FDA mandates warning labels for GLP-1 medications due to risk of rare eye condition

The FDA has mandated that all GLP-1 medications include warnings about a rare eye condition that can cause blindness. This requirement affects drugs such as Ozempic, Wegovy, and Mounjaro.

Companies
Novo Nordisk Eli Lilly Sanofi

Our neutral summary

The FDA has mandated that all GLP-1 medications include warnings about a rare eye condition that can cause blindness. This requirement affects drugs such as Ozempic, Wegovy, and Mounjaro.

Read the full story at Guardian — US

The reporting belongs to Guardian — US; we don't reproduce it.

Annotating as

Notes are private: only you can see them.

No note attached

of yours on this article.

Original vs. Neutral

Original Headline

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

Neutral Headline

FDA mandates warning labels for GLP-1 medications due to risk of rare eye condition